Manipal Health Enterprises, a prominent healthcare service provider, made a robust stock market debut on Wednesday, August 5, with its shares listing at a significant premium over the issue price. The company's initial public offering (IPO) generated considerable interest, culminating in a successful listing that surpassed initial market expectations.
Strong Market Debut for Healthcare Giant
Shares of Manipal Health Enterprises commenced trading on the Bombay Stock Exchange (BSE) at Rs 655, marking an impressive 11.02 percent premium over its issue price of Rs 590. Similarly, on the National Stock Exchange (NSE), the stock settled at Rs 652, reflecting a 10.51 percent premium. This strong performance allowed investors to realize a profit of Rs 1,625 on each lot, indicating a positive reception from the market despite earlier corrections in its Grey Market Premium (GMP).
IPO Details and Subscription Performance
The IPO of Manipal Health Enterprises was open for subscription from July 29 to July 31, with shares offered in a price band of Rs 560-590 per share. Investors could apply for a minimum lot size of 25 shares. The company successfully aimed to raise Rs 9,275 crore through the IPO, which comprised a fresh share sale of Rs 8,000 crore and an offer-for-sale (OFS) of up to 2,16,13,834 equity shares valued at Rs 1,275 crore.
The overall subscription for the issue reached nearly 4.92 times, attracting approximately 3.60 lakh applications. The Qualified Institutional Buyers (QIB) portion was notably oversubscribed at 8.25 times. Non-institutional investors subscribed 1.02 times, while the employee quota saw a subscription of 2.19 times. However, the retail portion lagged slightly, being subscribed 93 percent.
Expert Reactions and Future Outlook
Market analysts offered varied perspectives on the listing. Mahesh M. Ojha, VP of Research at Kantilal Chagganlal Securities, who had anticipated a more muted listing, advised,
“Allotted Investors may consider booking profits on any meaningful listing gains. Fresh investors are advised to wait for 1–2 quarters to gain better visibility on earnings growth, operational improvements, and a more attractive valuation before considering an entry.”
Prasenjit Paul, Fund Manager at 129 Wealth & Head of Research at Paul Asset, echoed a cautious sentiment for short-term gains, stating,
“Investors seeking listing gains may find the risk-reward unfavourable at the issue price. Those with a two-to-three-year horizon can monitor these execution triggers, because the present valuation leaves little margin for disappointment.”
About Manipal Health Enterprises
Incorporated in 2010 and headquartered in Bengaluru, Manipal Health Enterprises operates an extensive network of multi-speciality hospitals, clinics, and diagnostic centers across India. The company is renowned for providing comprehensive tertiary and quaternary care services, including organ transplants, oncology, cardiology, neurology, orthopaedics, and various preventive healthcare programs.